Press Releases

Press Releases

Samsung Biologics and Bristol-Myers Squibb Expand Manufacturing Aggreement

Samsung Biologics and Bristol-Myers Squibb Expand Manufacturing Aggreement

Bristol-Myers Squibb and Samsung Biologics 
Expand Manufacturing Agreement

 

(NEW YORK & SEOUL, South Korea ? April 22, 2014) - Bristol-Myers Squibb Company (NYSE:BMY) and Samsung Biologics today announced the companies will increase the scope of their existing manufacturing agreement in which Samsung will manufacture commercial drug substances and drug product for several Bristol-Myers Squibb biologic medicines at its Incheon manufacturing site. Financial terms of the agreement are not disclosed.

Bristol-Myers Squibb and Samsung announced their first manufacturing agreement in July 2013 to collaborate in the production of a single commercial antibody cancer drug substance. 

 

"Biologic medicines that treat serious diseases are an integral part of Bristol-Myers Squibb’s specialty care portfolio and R&D pipeline," said Lou Schmukler, president, Global Manufacturing & Supply. "The expanded relationship with Samsung will increase our biologics manufacturing capability and give us the flexibility to respond to increased demand in order to meet the global needs of patients." 

"Samsung is delighted to reach the second manufacturing agreement with Bristol-Myers Squibb and we look forward to delivering top quality GMP production," said Dr. TH Kim, president and CEO of Samsung Biologics. "It represents another significant step for Samsung and Bristol-Myers Squibb in strengthening our biopharmaceutical manufacturing relationship."

 

Samsung brings global biopharmaceutical capability through its fully-integrated production facilities that offer process development, drug substance manufacturing, and drug product fill & finish services at one location. In addition to its current biologics manufacturing facility in Incheon, Korea, the company is currently building a second facility, also in Incheon, which is expected to be completed in early 2015.?

 

About Bristol-Myers Squibb 

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bms.com or follow us on twitter at http://twitter.com/bmsnews. 

 

About Samsung Biologics 

Samsung Biologics is a global full-service provider of quality-driven contract process development and CGMP manufacturing to the global biopharmaceutical industry. Our facilities are custom designed for monoclonal & recombinant production with maximum flexibility. Our one-stop services include cell line generation, process and analytical method development, analytical services, clinical and commercial bulk CGMP manufacturing of drug substance and drug product including quality assurance, quality control, regulatory compliance standards & support for our customers. For additional information about the company, please visit

http://www.Samsung Biologics.com


 

Contacts 
 
Bristol-Myers Squibb
 
Media:
Laura Hortas, 609-252-4587, laura.hortas@bms.com
Ken Dominski, 609-252-5251, ken.dominski@bms.com
 
Investors:
Ranya Dajani, 609-252-5330, ranya.dajani@bms.com
Ryan Asay, 609-252-5020, ryan.asay@bms.com
 
Samsung Biologics
 
Media:
Jabin Yun, +82-32-455-3714, jabin.yun@samsung.com
Hoyeol(James) Yoon, + 82-32-455-3700, james63.yoon@samsung.com 

 

 

Samsung Biologics and Bristol-Myers Squibb Expand Manufacturing Aggreement

Bristol-Myers Squibb and Samsung Biologics 
Expand Manufacturing Agreement

 

(NEW YORK & SEOUL, South Korea – April 22, 2014) - Bristol-Myers Squibb Company (NYSE:BMY) and Samsung Biologics today announced the companies will increase the scope of their existing manufacturing agreement in which Samsung will manufacture commercial drug substances and drug product for several Bristol-Myers Squibb biologic medicines at its Incheon manufacturing site. Financial terms of the agreement are not disclosed.

Bristol-Myers Squibb and Samsung announced their first manufacturing agreement in July 2013 to collaborate in the production of a single commercial antibody cancer drug substance. 

 

"Biologic medicines that treat serious diseases are an integral part of Bristol-Myers Squibb’s specialty care portfolio and R&D pipeline," said Lou Schmukler, president, Global Manufacturing & Supply. "The expanded relationship with Samsung will increase our biologics manufacturing capability and give us the flexibility to respond to increased demand in order to meet the global needs of patients." 


"Samsung is delighted to reach the second manufacturing agreement with Bristol-Myers Squibb and we look forward to delivering top quality GMP production," said Dr. TH Kim, president and CEO of Samsung Biologics. "It represents another significant step for Samsung and Bristol-Myers Squibb in strengthening our biopharmaceutical manufacturing relationship."

 

Samsung brings global biopharmaceutical capability through its fully-integrated production facilities that offer process development, drug substance manufacturing, and drug product fill & finish services at one location. In addition to its current biologics manufacturing facility in Incheon, Korea, the company is currently building a second facility, also in Incheon, which is expected to be completed in early 2015.

 

About Bristol-Myers Squibb 

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bms.com or follow us on twitter at http://twitter.com/bmsnews. 

 

About Samsung Biologics 

Samsung Biologics is a global full-service provider of quality-driven contract process development and CGMP manufacturing to the global biopharmaceutical industry. Our facilities are custom designed for monoclonal & recombinant production with maximum flexibility. Our one-stop services include cell line generation, process and analytical method development, analytical services, clinical and commercial bulk CGMP manufacturing of drug substance and drug product including quality assurance, quality control, regulatory compliance standards & support for our customers. For additional information about the company, please visit

http://www.Samsung Biologics.com


 

Contacts 

 
Bristol-Myers Squibb
 
Media:
Laura Hortas, 609-252-4587, laura.hortas@bms.com
Ken Dominski, 609-252-5251, ken.dominski@bms.com
 
Investors:
Ranya Dajani, 609-252-5330, ranya.dajani@bms.com
Ryan Asay, 609-252-5020, ryan.asay@bms.com
 
Samsung Biologics
 
Media:
Jabin Yun, +82-32-455-3714, jabin.yun@samsung.com

Hoyeol(James) Yoon, + 82-32-455-3700, james63.yoon@samsung.com 

 

 

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Interests
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy required
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION